Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul T Edlefsen

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Nature Medicine|January 20, 2015
B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllersYoshinori Fukazawa, Richard Lum, Afam A Okoye, et al.
The Journal of Clinical Investigation|March 22, 2022
Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapyBenjamin D Varco-Merth, William Brantley, Alejandra Marenco, et al.
Plos One|October 29, 2014
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participantsKalpana Dommaraju, Gustavo Kijak, Jonathan M Carlson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2025
Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIVScott G Hansen, John B Schell, Emily E Marshall, et al.
The Journal of Clinical Investigation|February 25, 2021
CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplificationAfam A Okoye, Derick D Duell, Yoshinori Fukazawa, et al.
Science (New York, N.Y.)|March 26, 2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacyMarieke C Verweij, Scott G Hansen, Ravi Iyer, et al.
Nature Medicine|August 8, 2018
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral reboundAfam A Okoye, Scott G Hansen, Mukta Vaidya, et al.
Plos Pathogens|April 19, 2023
A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have wanedMegan A O'Connor, David W Hawman, Kimberly Meade-White, et al.
Science Translational Medicine|July 19, 2019
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challengeScott G Hansen, Emily E Marshall, Daniel Malouli, et al.
Nature Medicine|September 11, 2012
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccinesYoshinori Fukazawa, Haesun Park, Mark J Cameron, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Nature Medicine|January 20, 2015
B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllersYoshinori Fukazawa, Richard Lum, Afam A Okoye, et al.
The Journal of Clinical Investigation|March 22, 2022
Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapyBenjamin D Varco-Merth, William Brantley, Alejandra Marenco, et al.
Plos One|October 29, 2014
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participantsKalpana Dommaraju, Gustavo Kijak, Jonathan M Carlson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2025
Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIVScott G Hansen, John B Schell, Emily E Marshall, et al.
The Journal of Clinical Investigation|February 25, 2021
CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplificationAfam A Okoye, Derick D Duell, Yoshinori Fukazawa, et al.
Science (New York, N.Y.)|March 26, 2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacyMarieke C Verweij, Scott G Hansen, Ravi Iyer, et al.
Nature Medicine|August 8, 2018
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral reboundAfam A Okoye, Scott G Hansen, Mukta Vaidya, et al.
Plos Pathogens|April 19, 2023
A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have wanedMegan A O'Connor, David W Hawman, Kimberly Meade-White, et al.
Science Translational Medicine|July 19, 2019
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challengeScott G Hansen, Emily E Marshall, Daniel Malouli, et al.
Nature Medicine|September 11, 2012
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccinesYoshinori Fukazawa, Haesun Park, Mark J Cameron, et al.
Pageof 9